Latest news with #SwayampakulaRamakanth
Yahoo
4 days ago
- Business
- Yahoo
H.C. Wainwright Upgrades Vor Biopharma (VOR) to a Buy, Sets a $3 Price Target
Vor Biopharma Inc. (NASDAQ:VOR) is one of the . In a report released on June 30, Swayampakula Ramakanth from H.C. Wainwright upgraded Vor Biopharma Inc. (NASDAQ:VOR) to a Buy with a price target of $3.00. The analyst based the optimistic outlook on the company's growth potential and strategic advancements. A scientist in a lab coat looking through a microscope at a petri dish of hematopoietic stem cells. Vor Biopharma Inc. (NASDAQ:VOR) recently announced an exclusive license agreement with RemeGen Co. for the development and commercialization of telitacicept in regions outside of Greater China. Telitacicept is a promising recombinant fusion protein and has already exhibited clinical success, attaining marketing approvals in China for a number of conditions, including generalized myasthenia gravis, systemic lupus nephritis, and rheumatoid arthritis. The analyst further reasoned that the financial structure of the agreement lends Vor Biopharma Inc. (NASDAQ:VOR) financial strength because it includes upfront payments and potential milestone payments. Vor Biopharma Inc. (NASDAQ:VOR) is a clinical-stage cell therapy company that develops cell therapies for the treatment of cancer. It combines therapies with a novel patient engineering approach to provide a single company solution for hematological malignancies. While we acknowledge the potential of VOR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
25-06-2025
- Business
- Yahoo
Nuvalent price target raised to $130 from $110 at H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth raised the firm's price target on Nuvalent (NUVL) to $130 from $110 and keeps a Buy rating on the shares. The company reported positive topline results from the Phase 1/2 ARROS-1 study evaluating zidesamtinib to treat ROS1-positive non-small cell lung cancer patients that have received prior (tyrosine kinase inhibitor therapy, the analyst tells investors in a research note. The firm says the overall response rate among all patients is 44%, and the patients showed good durability with duration of responses of 78% at 12 months and 62% at 18 months. H.C. Wainwright believes the data was 'particularly encouraging' in the 55 patients who received only one prior line of TKI therapy, who achieved overall response rate of 51% and an 18- month duration of response of 93%. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today's best-performing stocks on TipRanks >> Read More on NUVL: Disclaimer & DisclosureReport an Issue Nuvalent's Zidesamib: Promising Best-in-Class ROS1 TKI with Strong Efficacy and Safety Profile Nuvalent Announces Positive Data for Zidesamtinib Trial Nuvalent Announces New Director and Annual Meeting Results Nuvalent's Zidesamtinib: Promising Efficacy and Safety Drive Buy Rating Nuvalent Board Member Emily Conley Resigns Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
